Commensal bacteria and cancer immunotherapy: strategy and opportunity
Xusheng Zhang, Xiwen Qin, Shuo Wang
Commensal bacteria and cancer immunotherapy: strategy and opportunity
[1] |
Zitvogel L, Daillere R, Roberti MP, et al. Anticancer effects of the microbiome and its products. Nat Rev Microbiol 2017;15:465–78.
CrossRef
Google scholar
|
[2] |
Lam KC, Araya RE, Huang A, et al. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell 2021;184:5338–5356.e21.
CrossRef
Google scholar
|
[3] |
Zhang X, Yu D, Wu D, et al. Tissue-resident Lachnospiraceae family bacteria protect against colorectal carcinogenesis by promoting tumor immune surveillance. Cell Host Microbe 2023;31:418–432.e8.
CrossRef
Google scholar
|
[4] |
Mager LF, Burkhard R, Pett N, et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 2020;18:1481–9.
CrossRef
Google scholar
|
[5] |
Tanoue T, Morita S, Plichta DR, et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 2019;565:600–5.
CrossRef
Google scholar
|
/
〈 | 〉 |